TLR3 Agonist Poly-IC Induces IL-33 and Promotes Myelin Repair

PLoS One. 2016 Mar 29;11(3):e0152163. doi: 10.1371/journal.pone.0152163. eCollection 2016.

Abstract

Background: Impaired remyelination of demyelinated axons is a major cause of neurological disability. In inflammatory demyelinating disease of the central nervous system (CNS), although remyelination does happen, it is often incomplete, resulting in poor clinical recovery. Poly-IC a known TLR3 agonist and IL-33, a cytokine which is induced by poly-IC are known to influence recovery and promote repair in experimental models of CNS demyelination.

Methodology and principal findings: We examined the effect of addition of poly-IC and IL-33 on the differentiation and maturation of oligodendrocyte precursor cells (OPC) cultured in vitro. Both Poly-IC and IL-33 induced transcription of myelin genes and the differentiation of OPC to mature myelin forming cells. Poly-IC induced IL-33 in OPC and addition of IL-33 to in vitro cultures, amplified further, IL-33 expression suggesting an autocrine regulation of IL-33. Poly-IC and IL-33 also induced phosphorylation of p38MAPK, a signaling molecule involved in myelination. Following the induction of gliotoxic injury with lysolecithin to the corpus callosum (CC), treatment of animals with poly-IC resulted in greater recruitment of OPC and increased staining for myelin in areas of demyelination. Also, poly-IC treated animals showed greater expression of IL-33 and higher expression of M2 phenotype macrophages in the CC.

Conclusion/significance: Our studies suggest that poly-IC and IL-33 play a role in myelin repair by enhancing expression of myelin genes and are therefore attractive therapeutic agents for use as remyelinating agents in human demyelinating disease.

MeSH terms

  • Animals
  • Cell Differentiation / drug effects
  • Cell Nucleus / drug effects
  • Cell Nucleus / metabolism
  • Cell Polarity / drug effects
  • Cells, Cultured
  • Corpus Callosum / drug effects
  • Corpus Callosum / metabolism
  • Enzyme Activation / drug effects
  • Intercellular Signaling Peptides and Proteins / pharmacology
  • Interleukin-33 / metabolism*
  • Lysophosphatidylcholines / pharmacology
  • Macrophages / drug effects
  • Macrophages / metabolism
  • Models, Biological
  • Myelin Basic Protein / metabolism
  • Myelin Sheath / drug effects
  • Myelin Sheath / metabolism*
  • Neuroglia / drug effects
  • Neuroglia / metabolism
  • Oligodendroglia / drug effects
  • Oligodendroglia / metabolism
  • Phenotype
  • Phosphorylation / drug effects
  • Poly I-C / pharmacology*
  • Rats, Sprague-Dawley
  • Real-Time Polymerase Chain Reaction
  • Recombinant Proteins / pharmacology
  • Stem Cells / drug effects
  • Stem Cells / metabolism
  • Toll-Like Receptor 3 / agonists*
  • Toll-Like Receptor 3 / metabolism
  • Transcription, Genetic / drug effects
  • Up-Regulation / drug effects
  • Wound Healing / drug effects*
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Intercellular Signaling Peptides and Proteins
  • Interleukin-33
  • Lysophosphatidylcholines
  • Myelin Basic Protein
  • Recombinant Proteins
  • Toll-Like Receptor 3
  • p38 Mitogen-Activated Protein Kinases
  • Poly I-C

Grants and funding

The authors have no support or funding to report.